Monopar Therapeutics Inc 2025年季度报告

Large accelerated filer☐Accelerated filer☐Non-accelerated Filer☒Smaller reporting company☒Emerging growth company☐ March 31, 2025 and 2024Condensed Consolidated Statements of Stockholders’Equity for the ThreeMonths Ended March 31, 2025 Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2025 and 2024Notes to Condensed Consolidated Financial Statements Management’s Discussion and Analysis of Financial Condition and Results of OperationsControls and ProceduresOTHER INFORMATIONItem 1A.Risk FactorsOther InformationExhibits 2 than statements of historical facts included in this Quarterly Report on Form 10-Q are forward-looking statements. The words“hopes,” “believes,” “anticipates,” “plans,” “seeks,” “estimates,” “projects,” “expects,” “intends,” “may,” “could,” “should,” “would,”“will,”“continue,”and similar expressions are intended to identify forward-looking statements. The followinguncertainties and factors, among others, could affect future performance and cause actual results to differ materially from thosematters expressed in or implied by forward-looking statements:●ourability to raise sufficient funds in order for us to support continued clinical, regulatory and commercialdevelopment of our programs and to make contractualfuture milestone payments, as well as our ability to furtherraise additional funds in the future to support any existing or future productcandidate programs through completionof clinical trials, the approval processes and, ifapplicable, commercialization;●our ability to raise funds on acceptable terms; ●our ability to find a suitable pharmaceutical partner or partners to further our development efforts, under acceptablefinancial terms;●risks and uncertainties associated with our or any development partners’research and development activities, ●knownand unknown risks associated with developing copper-chelating therapies and radiopharmaceuticaltherapeutics and imaging agents; ●uncertainties related to the regulatory discussions we may initiate related to ALXN1840 and the outcome(s) thereof; (“NDA”) for ALXN1840; ●our ability to obtain an adequate supply at reasonable costs of radioisotopes that we are currently using or that we ●the difficulties of commercialization, marketing and product manufacturing and overall strategy;●uncertainties of intellectual property position and strategy including new discoveries and patent filings; ●the risks inherent in our estimates regarding the level of needed expenses, capital requirements and the availabilityof required additional financing at acceptable terms or at all;●U.S. political leadership developments may affect the economy and future laws, tariffs, and regulations or executiveorders, and may in turn lead to increased or decreased governmental control of healthcare and pharmaceuticals, acting on our behalf are expressly qualified in their entirety by the cautionary statements. We undertake no obligation to updateany statements made in this Quarterly Report on Form 10-Q or elsewhere, including without limitation any forward-lookingstatements, except as required by law. results, performance or achievements to be materially different from any future results, performance or achievements expressed orimplied by theseforward-looking statements. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from eventsand circumstances projected in this information.4 Statements of Operations and Comprehensive Loss(Unaudited) AdditionalOtherCommon StockPaid-inComprehensiveAccumulatedStockholSharesAmountCapitalIncome(Loss)DeficitEquity Issuance of common stock to employees pursuantto vested restricted stock units, net of taxes8,4878(131,137)——(131,129)1,355,011,355,01 Issuance of common stock upon exercise of stock ————(2,624,972)Other comprehensive loss———(57,776)—Balance at March 31, 20256,115,214$6,115$132,026,635$(21,784)$(78,417,608)$53,593,3 (Unaudited)Accumul AdditionalOtherCommon Stock**Paid-inComprehensiveAccumulatedStockholSharesAmountCapital**Income(Loss)DeficitEquity DemandTMSales Agreement with JonesTradingInstitutional Services, LLC, net of commissions, Issuance of common stock to employees pursuantto vested restricted stock units, net of taxes Net loss Other comprehensive income Balance at March 31, 20246$3,496$69,316,851$4,231$443)$7,477,13**Information pertaining to number of shares outstanding gives retroactive effect to a 1 for 5 reverse stock split that becameeffective on August 12, 2024.The accompanying notes are an integral part of these condensed consolidated financial statements. For the Three Months Ended Cash flows from operating activities: $(2,624,972)$(1,641,226)Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation expense, net1,355,017 In-process research and development accrued